13F Holdings
中文EN

CWLXF C21 Investments Inc. Annual reports only

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 831609 · Fiscal year ends 03/31

Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.3%
TTM net income YoY18.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin41.7%
Operating margin7.0%
Net margin-9.9%
FCF margin3.4%
EBITDA margin12.4%

Returns

ROE-12.0%
ROA-5.8%
ROIC (approx.)4.6%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage12.17x

Cash quality & payout

Operating cash flow / net income-0.42x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-03-31FY20252025-03-31FY20242024-01-31FY20232023-01-31FY20222022-01-31
Income statement
Revenue$32.61M$30.12M$28.29M$28.89M$32.98M
Cost of revenue$19.01M$17.56M$17.14M$15.49M$14.17M
Gross profit$13.61M$12.56M$11.15M$13.40M$18.81M
SG&A expense$11.33M$11.28M$9.68M$9.45M$9.06M
Operating income$2.28M$1.28M$1.47M$3.96M$9.75M
Interest expense$187,241$293,675$35,210$456,691$1.08M
Pretax income$1.38M$394,921$258,657$4.19M$17.13M
Income tax$4.61M$4.15M$3.48M$2.81M$4.93M
Net income-$3.24M-$3.97M-$3.31M$293,211$9.95M
EBITDA$4.06M$2.99M$2.88M$5.80M$11.57M
EPS (basic)-0.03-0.03-0.030.000.08
EPS (diluted)-0.03-0.03-0.030.000.08
Weighted avg. shares (diluted)118.47M120.59M122.88M122.88M121.14M
Balance sheet
Cash & equivalents$2.23M$2.63M$2.41M$1.89M$3.07M
Receivables$57,084$124,827$189,192$401,476$198,478
Inventory$4.59M$4.05M$2.71M$4.17M$4.05M
Current assets$8.31M$7.50M$7.24M$8.60M$10.28M
PP&E, net$2.30M$2.67M$3.43M$4.69M$4.87M
Goodwill$28.54M$28.54M$28.54M$28.54M$28.54M
Intangibles$6.41M$8.09M$6.48M$7.89M$9.22M
Total assets$54.42M$57.00M$54.53M$58.31M$61.84M
Current liabilities$6.39M$7.96M$14.17M$14.97M$15.97M
Total liabilities$28.99M$28.32M$23.48M$24.00M$28.12M
Shareholders' equity$25.43M$28.68M$31.05M$34.32M$33.73M
Shares outstanding117.84M118.00M120.05M120.05M120.05M
Cash flow statement
Operating cash flow$1.36M$1.37M$3.26M$5.97M$8.44M
Capital expenditure$244,838$406,733$521,579$442,285$2.56M
Free cash flow$1.12M$958,920$2.74M$5.53M$5.88M
Investing cash flow-$219,838-$3.45M-$121,579-$442,285-$2.56M
Financing cash flow-$1.54M$1.67M-$2.65M-$6.63M-$7.74M
Depreciation & amortization$1.78M$1.71M$1.41M$1.84M$1.82M
Stock-based compensation$236,779$849,559$22,128$209,441$366,469
Share buybacks$103,034$276,730$0——

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.